


IR Earning Call | 2025.1Q

ST PHARM

Technology Driven Gene therapy CDMO
From Oligonucleotide to xRNA



Cautionary Statement regarding Forward-looking Statement

This presentation contains forward-looking statements from Dong-A Socio Group ("the Group") that include, but are not limited to, statements regarding our future financial performance, business strategies, market opportunities, product development, and operational plans. Words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "project," "will," and similar expressions are intended to identify such forward-looking statements.


These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effects on the Group. Such forward-looking statements are inherently subject to risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed in these forward-looking statements.

We caution investors not to place undue reliance on any forward-looking statements. These statements speak only as of the date they are made, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Additionally, please note that the financial figures and metrics presented in these Investor Relations materials are preliminary and have not yet been audited by an independent auditor. These numbers may be subject to change in future finalized disclosures.



Consolidated Financial Results

Quarterly Performance Trend



Financial Statement

1Q Revenue ₩52.4B, Operating Profit ₩1.0B, Net Profit ₩0.7B

- 1) Margins declined from increased cost (R&D expense, inventory disposal, etc.)
2) Subsidiaries reported losses of 1.7B KRW, reducing losses from 3.6B KRW in 1Q.24

(Unit: 1 Billion KRW)

Category	'25.1Q	'24.1Q	2024	YoY
Revenue	52.4	51.7	273.8	1.4%
Cost of Goods Sold	33.2	32.7	177.6	1.3%
Gross Profit	19.3	19.0	96.2	1.4%
SG&A Expenses	18.2	17.1	68.5	6.5%
R&D Expenses	5.5	5.0	22.1	11.2%
Operating Profit	1.0	1.9	27.7	-45.5%
Net Profit	0.7	5.4	32.5	-86.9%
Gross Profit Margin	36.8%	36.7%	35.1%	0.1%p
Operating Profit Margin	2.0%	3.6%	10.1%	-1.7%p
Net Profit Margin	1.4%	10.5%	11.9%	-9.1%p

Earning Result

2025 1Q Financial Results by Segments (Preliminary)

Business Segment Breakdown

(Unit: 1 Billion KRW)

Sector	'24.1Q	'24.2Q	'24.3Q	'24.4Q	'25.1Q	YoY
Subtotal (% of Revenue)	34.5 (66.8%)	23.8 (53.3%)	35.6 (58.1%)	81.3 (69.7%)	37.6 (71.7%)	8.9%
Oligo. CDMO						
Commercial	7.9	13.1	29.6	62.9	32.4	321.7%
Clinical	26.7	10.7	5.9	18.5	5.1	-80.7%
Small Molecule API (SMA)	4.4	1.6	8.8	10.9	1.1	-73.6%
mRNA	0.0	0.3	0.8	0.4	0.6	1184.9%
Generic API (GA)	5.1	7.4	12.0	15.2	5.3	5.5%
Others	0.0	0.5	0.0	0.4	0.0	-47.6%
Separate Revenue	44.1	33.6	57.2	108.3	44.7	1.5%
Subsidiaries (CRO)	7.6	10.9	4.0	9.7	7.7	0.7%
Consolidated Revenue	51.7	44.6	61.2	117.9	52.4	1.4%

Comments

Oligo API CDMO business sales increased 8.9% YoY

- Oligonucleotide API
Backlog status: \$232.7M (+\$78.5M in 2025)
Stable sales growth from commercial projects continues
Anticipating sales growth in clinical projects
- Small Molecule API & Generic API
[SM] Absence of mitochondrial deficiency project sales compared to 1Q.24 main reason for sales contraction
Full-year expectations unchanged
- CRO Subsidiaries
New order growth signal steady recovering demand
(25.2B KRW (2023) → 40.1B KRW (2024))
- Anticipated Events in 2025
[Oligo] HAE project (NDA), FCS/sHTG project (P3 results)
[SM] Mitochondrial deficiency project (NDA)
[Pipeline] Pirmitegravir (P2 interim results)

Thank You

ST PHARM

Technology-Driven Gene therapy CDMO
From Oligonucleotide to xRNA

